Evidence map›Paper›PMID 40485910›Full record

ArticleClinical and translational radiation oncology2025

In vitro measurement of proton RBE: A multi-centric comparison using a harmonized setup.

Olga Sokol, Anders Tobias Frederiksen, Mateusz Sitarz, Brita Singers Sørensen, Elham Santina, Christopher Smith, John-William Warmenhoven, Marie Davídková, Anna Jelínek Michaelidesová, Irina Danilová and 19 more

Abstract read
In one paragraph

Article in Clinical and translational radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Olga SokolGSI Helmholtz Centre for Heavy Ion Research, Darmstadt, Germany.
Anders Tobias FrederiksenDepartment of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark.
Mateusz SitarzDanish Centre for Particle Therapy (DCPT), Aarhus University Hospital, Aarhus Denmark.
Brita Singers SørensenDepartment of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark.
Elham SantinaDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
Christopher SmithDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
John-William WarmenhovenDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
Marie DavídkováNuclear Physics Institute of the Czech Academy of Sciences, Řež, Czech Republic.
Anna Jelínek MichaelidesováNuclear Physics Institute of the Czech Academy of Sciences, Řež, Czech Republic.
Irina DanilováNuclear Physics Institute of the Czech Academy of Sciences, Řež, Czech Republic.
Oldřich ZahradníčekNuclear Physics Institute of the Czech Academy of Sciences, Řež, Czech Republic.
Amélia Maia LeiteInserm U1021 - CNRS UMR 3347, Institut Curie, PSL Research University, University Paris Saclay, Orsay, France.
Ludovic de MarziInstitut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, Centre universitaire, Orsay, France.
Frederic PouzouletInserm U1288, Laboratory of Translational Imaging in Oncology (LITO), Institut Curie, PSL Research University, University Paris Saclay, Orsay, France.
Paweł OlkoInstitute of Nuclear Physics Polish Academy of Sciences, Krakow, Poland.
Justyna MiszczykInstitute of Nuclear Physics Polish Academy of Sciences, Krakow, Poland.
Barbara OrzechowskaInstitute of Nuclear Physics Polish Academy of Sciences, Krakow, Poland.
Eleftherios PapalanisDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Mehran HaririDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Diana SpiegelbergDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Bo StenerlöwDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Alexandru DasuDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Elisabeth BodensteinHelmholtz-Zentrum Dresden - Rossendorf (HZDR), Institute of Radiooncology - OncoRay, Dresden, Germany.
Elke BeyreutherOncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany.
Jörg PawelkeHelmholtz-Zentrum Dresden - Rossendorf (HZDR), Institute of Radiooncology - OncoRay, Dresden, Germany.
Dorothee PfitzmannDepartment of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Karen KirkbyDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
Nicholas HenthornDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
Marco DuranteGSI Helmholtz Centre for Heavy Ion Research, Darmstadt, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: This study presents a multi-center comparison of in vitro cell survival measurements and RBE calculations following proton irradiations conducted under harmonized experimental conditions across six European institutions participating in the INSPIRE framework. Materials and methods: V79-4 cells were irradiated using spread-out Bragg peak (SOBP) proton fields of two configurations delivering 6 and 8 Gy with widths of 6 and 4 cm, respectively. Each center adhered to a standardized protocol, utilizing the same phantom design to minimize uncertainties related to sample positioning. X-ray reference irradiations were also performed to assess cell radiosensitivity across the participating centers. Results: Despite the consistent protocol, significant inter-institutional variability was observed in the survival measurements. For both treatment plans, the largest variation was detected in the most distal points of the SOBP (coefficients of variation of 43 % and 60 % for the 6 Gy and 8 Gy plans, respectively). Kruskal-Wallis statistical test confirmed the significant differences between the centers for each of the measured position in the proton field for both SOBP configurations. Discrepancies were observed in calculated RBE data as well, albeit preserving the expected trend for the values to slightly increase towards the distal edge of the SOBP (up to 1.5 and 1.3 for the 6 Gy and 8 Gy plans, respectively). Conclusion: The results of the study highlight the minimal biological variation one could expect performing proton RBE measurements in well-aligned experimental conditions and challenges in conducting large-scale, multi-center radiobiological experiments and inter-comparisons between literature data sets.

Indexed as

Cell survivalProton therapyRelative biological effectiveness

Identifiers

PMID40485910
PMCPMC12141100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.